Intra-Cellular Therapies Inc. (NASDAQ:ITCI)‘s stock had its “hold” rating restated by investment analysts at SunTrust Banks, Inc. in a research report issued on Friday. They presently have a $22.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $16.00. SunTrust Banks, Inc.’s price objective would suggest a potential upside of 2.85% from the stock’s previous close.

ITCI has been the subject of several other research reports. Piper Jaffray Companies set a $10.00 target price on shares of Intra-Cellular Therapies and gave the company a “hold” rating in a research note on Thursday, August 10th. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Intra-Cellular Therapies in a research note on Wednesday, August 9th. BidaskClub downgraded shares of Intra-Cellular Therapies from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. Cowen and Company reaffirmed an “outperform” rating and issued a $27.00 target price (up previously from $20.00) on shares of Intra-Cellular Therapies in a research note on Friday. Finally, ValuEngine raised shares of Intra-Cellular Therapies from a “strong sell” rating to a “sell” rating in a research note on Friday, August 18th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $28.00.

Intra-Cellular Therapies (NASDAQ ITCI) traded down 3.21% during trading on Friday, reaching $21.39. 828,691 shares of the company were exchanged. Intra-Cellular Therapies has a 52-week low of $7.85 and a 52-week high of $45.20. The firm’s market cap is $928.84 million. The firm has a 50-day moving average of $13.42 and a 200-day moving average of $12.73.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.74) by $0.33. The business had revenue of $0.11 million during the quarter, compared to the consensus estimate of $0.03 million. Intra-Cellular Therapies had a negative net margin of 32,834.94% and a negative return on equity of 27.92%. Intra-Cellular Therapies’s revenue for the quarter was down 52.2% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.71) earnings per share. On average, equities analysts forecast that Intra-Cellular Therapies will post ($2.36) EPS for the current year.

WARNING: “Intra-Cellular Therapies’ (ITCI) “Hold” Rating Reaffirmed at SunTrust Banks, Inc.” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.americanbankingnews.com/2017/09/08/intra-cellular-therapies-itci-hold-rating-reaffirmed-at-suntrust-banks-inc.html.

Several institutional investors have recently added to or reduced their stakes in the company. Wasatch Advisors Inc. boosted its holdings in shares of Intra-Cellular Therapies by 65.1% in the second quarter. Wasatch Advisors Inc. now owns 1,659,513 shares of the biopharmaceutical company’s stock valued at $20,611,000 after buying an additional 654,400 shares during the period. State Street Corp boosted its holdings in shares of Intra-Cellular Therapies by 10.4% in the second quarter. State Street Corp now owns 1,004,360 shares of the biopharmaceutical company’s stock valued at $12,474,000 after buying an additional 94,763 shares during the period. Janus Henderson Group PLC acquired a new position in shares of Intra-Cellular Therapies in the second quarter valued at approximately $435,000. Fred Alger Management Inc. acquired a new position in shares of Intra-Cellular Therapies in the second quarter valued at approximately $161,000. Finally, Samlyn Capital LLC boosted its holdings in shares of Intra-Cellular Therapies by 58.7% in the second quarter. Samlyn Capital LLC now owns 537,200 shares of the biopharmaceutical company’s stock valued at $6,672,000 after buying an additional 198,700 shares during the period. Institutional investors own 71.79% of the company’s stock.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

Analyst Recommendations for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.